Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Extension of Indications for Crizotinib

Two new indications concern the treatment of paediatric patients with ALK-positive anaplastic large cell lymphoma and inflammatory myofibroblastic tumour
23 Sep 2022
Cancer in Special Situations / Population;  Personalised medicine

On 15 September 2022, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product crizotinib (Xalkori).

The marketing authorisation holder for this medicinal product is Pfizer Europe MA EEIG.

The CHMP adopted 2 new indications for the treatment of paediatric patients with anaplastic large cell lymphoma (ALCL) or inflammatory myofibroblastic tumour (IMT).

For information, the full indications for Xalkori will therefore be as follows (new indications in bold):

Xalkori as monotherapy is indicated for:

  • The first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
  • The treatment of adults with previously treated ALK-positive advanced NSCLC
  • The treatment of adults with ROS1-positive advanced NSCLC
  • The treatment of paediatric patients (age ≥6 to <18 years) with relapsed or refractory systemic ALK-positive ALCL
  • The treatment of paediatric patients (age ≥6 to <18 years) with recurrent or refractory ALK‑positive unresectable IMT

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics, which will be published in the revised European public assessment report, and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.